Trial Profile
A Phase 2, Multi-center, Single Arm, Histologically Controlled Study Testing the Combination of TTFields and Pulsed Bevacizumab Treatment in Patients With Bevacizumab-refractory Recurrent Glioblastoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Jun 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 10 Aug 2021 Status changed from active, no longer recruiting to discontinued due to stagnant enrollment.
- 28 Jun 2021 Status changed from recruiting to active, no longer recruiting.
- 02 Nov 2020 Planned End Date changed from 15 Mar 2021 to 15 Mar 2022.